Stephanie J Nakano1, Shelley D Miyamoto1, Matthew Movsesian1, Penny Nelson1, Brian L Stauffer1, Carmen C Sucharov2. 1. From the Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora (S.J.N., S.D.M.); Cardiology Section, Veterans Affairs Salt Lake City Health Care System and the Departments of Internal Medicine (Cardiology) and Pharmacology, University of Utah School of Medicine (M.M.); Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora (P.N., B.L.S., C.C.S.); and Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, CO (B.L.S.). 2. From the Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora (S.J.N., S.D.M.); Cardiology Section, Veterans Affairs Salt Lake City Health Care System and the Departments of Internal Medicine (Cardiology) and Pharmacology, University of Utah School of Medicine (M.M.); Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora (P.N., B.L.S., C.C.S.); and Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, CO (B.L.S.). kika.sucharov@ucdenver.edu.
Abstract
BACKGROUND: Despite the application of proven adult heart failure therapies to children with idiopathic dilated cardiomyopathy (IDC), prognosis remains poor. Clinical experience with phosphodiesterase 3 inhibitors (PDE3i) in pediatric patients with IDC, however, demonstrates improved heart failure symptoms without the increased incidence of sudden death seen in adults treated with PDE3i. We sought to determine age-related differences in PDE activity and associated intracellular signaling responsible for the efficacy and relative safety of chronic PDE3i in pediatric heart failure. METHODS AND RESULTS: cAMP levels, PDE activity, and phospholamban phosphorylation (pPLB) were determined in explanted human left ventricular myocardium (pediatric n=41; adult n=88). Adults and children with IDC (not treated with PDE3i) had lower cAMP and pPLB compared with nonfailing controls. In contrast to their adult counterparts, pediatric IDC patients chronically treated with PDE3i had elevated cAMP (P=0.0403) and pPLB (P=0.0119). In addition, total PDE- and PDE3-specific activities were not altered in pediatric IDC patients on PDE3i, whereas adult IDC patients on PDE3i demonstrated higher total PDE-specific (74.6±13.8 pmol/mg per minute) and PDE3-specific (48.2±15.9 pmol/mg per minute) activities in comparison with those of nonfailing controls (59.5±14.4 and 35.5±12.8 pmol/mg per minute, respectively). CONCLUSIONS: Elevated cAMP and higher pPLB may contribute to sustained hemodynamic benefits in pediatric IDC patients treated with PDE3i. In contrast, higher total PDE and PDE3 activities in adult IDC patients treated with PDE3i may perpetuate lower myocardial cAMP and pPLB levels, limiting the potential benefits of PDE3i therapy.
BACKGROUND: Despite the application of proven adult heart failure therapies to children with idiopathic dilated cardiomyopathy (IDC), prognosis remains poor. Clinical experience with phosphodiesterase 3 inhibitors (PDE3i) in pediatric patients with IDC, however, demonstrates improved heart failure symptoms without the increased incidence of sudden death seen in adults treated with PDE3i. We sought to determine age-related differences in PDE activity and associated intracellular signaling responsible for the efficacy and relative safety of chronic PDE3i in pediatric heart failure. METHODS AND RESULTS:cAMP levels, PDE activity, and phospholamban phosphorylation (pPLB) were determined in explanted human left ventricular myocardium (pediatric n=41; adult n=88). Adults and children with IDC (not treated with PDE3i) had lower cAMP and pPLB compared with nonfailing controls. In contrast to their adult counterparts, pediatric IDC patients chronically treated with PDE3i had elevated cAMP (P=0.0403) and pPLB (P=0.0119). In addition, total PDE- and PDE3-specific activities were not altered in pediatric IDC patients on PDE3i, whereas adult IDC patients on PDE3i demonstrated higher total PDE-specific (74.6±13.8 pmol/mg per minute) and PDE3-specific (48.2±15.9 pmol/mg per minute) activities in comparison with those of nonfailing controls (59.5±14.4 and 35.5±12.8 pmol/mg per minute, respectively). CONCLUSIONS: Elevated cAMP and higher pPLB may contribute to sustained hemodynamic benefits in pediatric IDC patients treated with PDE3i. In contrast, higher total PDE and PDE3 activities in adult IDC patients treated with PDE3i may perpetuate lower myocardial cAMP and pPLB levels, limiting the potential benefits of PDE3i therapy.
Authors: Ryan Hambleton; Judith Krall; Eliso Tikishvili; Matthew Honeggar; Faiyaz Ahmad; Vincent C Manganiello; Matthew A Movsesian Journal: J Biol Chem Date: 2005-09-19 Impact factor: 5.157
Authors: M Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; G H Hendrix; W J Bommer; U Elkayam; M L Kukin Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245
Authors: Xuan Jiang; Juliana Sucharov; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov Journal: Am J Physiol Heart Circ Physiol Date: 2017-01-27 Impact factor: 4.733
Authors: Kathleen C Woulfe; Cortney E Wilson; Shane Nau; Sarah Chau; Elisabeth K Phillips; Shulun Zang; Christine Tompkins; Carmen C Sucharov; Shelley D Miyamoto; Brian L Stauffer Journal: Am J Physiol Heart Circ Physiol Date: 2018-07-20 Impact factor: 4.733
Authors: Elizabeth Medina; Carmen C Sucharov; Penny Nelson; Shelley D Miyamoto; Brian L Stauffer Journal: J Pediatr Date: 2016-11-29 Impact factor: 4.406
Authors: Philip D Tatman; Kathleen C Woulfe; Anis Karimpour-Fard; Danielle A Jeffrey; James Jaggers; Joseph C Cleveland; Karin Nunley; Matthew Rg Taylor; Shelley D Miyamoto; Brian L Stauffer; Carmen C Sucharov Journal: JCI Insight Date: 2017-07-20
Authors: Stephanie J Nakano; Juliana Sucharov; Robert van Dusen; Mackenzie Cecil; Karin Nunley; Sean Wickers; Anis Karimpur-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov Journal: J Card Fail Date: 2016-07-15 Impact factor: 5.712